EA
CORT icon

Emerald Acquisition’s Corcept Therapeutics CORT Stock Holding History

Emerald Acquisition’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$923K Sell
141,955
-2,457
-2% -$14.3K ﹤0.01% 2164
2016
Q2 		$788K Buy
+144,412
New +$751K ﹤0.01% 2283

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Emerald Acquisition's CORT Position: Q3 2016 in Review

Emerald Acquisition reduced its Corcept Therapeutics (CORT) stake by 1.7% in Q3 2016, selling an estimated $14.3K and leaving 141,955 shares worth $923K. The position accounts for ﹤0.01% of the portfolio, ranked #2164.

Emerald Acquisition first reported a position in CORT in Q2 2016 and has held it in 2 quarters since. 110 funds tracked by Wall St. Rank hold CORT as of Q3 2016.

  • Emerald Acquisition held 141,955 shares of Corcept Therapeutics worth $923K as of Q3 2016.
  • Emerald Acquisition sold 2,457 Corcept Therapeutics shares in Q3 2016, an estimated $14.3K.
  • Corcept Therapeutics made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2164 holding.
  • Emerald Acquisition first reported a position in Corcept Therapeutics in Q2 2016 and has held it in 2 quarters since.
  • 110 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.